Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis
Authors
Keywords
Ovarian cancer, Cancer chemotherapy, Meta-analysis, Prognosis, Histology, Cancer treatment, Platinum, Chemotherapy
Journal
PLoS One
Volume 11, Issue 11, Pages e0166058
Publisher
Public Library of Science (PLoS)
Online
2016-11-04
DOI
10.1371/journal.pone.0166058
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multidrug resistance-associated biomarkers PGP, GST-π, Topo-II and LRP as prognostic factors in primary ovarian carcinoma
- (2016) D. Lu et al. BRITISH JOURNAL OF BIOMEDICAL SCIENCE
- Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
- (2015) Karolina Tecza et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma
- (2014) Koji Matsuo et al. GYNECOLOGIC ONCOLOGY
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) J. A. Ledermann et al. ANNALS OF ONCOLOGY
- Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome
- (2013) K. L. White et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas
- (2013) Sharon E. Johnatty et al. GYNECOLOGIC ONCOLOGY
- Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum
- (2012) Ahmed Y. Ali et al. Annals of the New York Academy of Sciences
- Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
- (2012) Man Yu et al. CANCER AND METASTASIS REVIEWS
- Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistancein vitroandin vivo
- (2012) Ke-Jun Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein
- (2012) Britta Stordal et al. PLoS One
- Improving Cancer Chemotherapy with Modulators of ABC Drug Transporters
- (2011) S. Shukla et al. CURRENT DRUG TARGETS
- Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer
- (2011) Troels K. Bergmann et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study
- (2011) Chunqiao Tian et al. GYNECOLOGIC ONCOLOGY
- Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas
- (2011) D. A. Zajchowski et al. MOLECULAR CANCER THERAPEUTICS
- ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy
- (2008) S. E. Johnatty et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search